Cancer‐associated kinase domain variants in the epidermal growth factor receptor (EGFR) are common in non‐small‐cell lung cancer (NSCLC) as they can result in the increased ligand‐independent kinase activity of the receptor. Here, EGFR is linked to non-small cell lung carcinoma.